OGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Organon & Co is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance shows significant declines in net income and EPS, and there are no strong positive catalysts or trading signals to support immediate action. Holding or waiting for further clarity is recommended.
The stock shows bearish technical indicators: MACD is negatively expanding, RSI is neutral at 34.736, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 7.434, with key support at 6.769 and resistance at 8.098.
Organon's licensing of MIUDELLA®, a hormone-free copper IUD, for $27.5 million with potential milestone payments up to $505 million, could enhance its women's health portfolio.
The company's financials for Q3 2025 show a significant decline in net income (-55.43% YoY) and EPS (-55.80% YoY), along with a drop in gross margin (-8.30% YoY). Analysts maintain an Underweight rating, and there are no recent significant hedge fund or insider trading trends.
In Q3 2025, revenue increased slightly by 1.26% YoY to $1.602 billion. However, net income dropped significantly by -55.43% YoY to $160 million, and EPS fell by -55.80% YoY to 0.61. Gross margin also declined to 53.5%, down -8.30% YoY.
Barclays raised the price target to $8 from $7.50 but maintained an Underweight rating. Analysts see the sector in a transition phase, with easing pricing headwinds and improving investor sentiment, but remain cautious on Organon.
